<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mult Scler</journal-id><journal-id journal-id-type="iso-abbrev">Mult. Scler</journal-id><journal-id journal-id-type="publisher-id">MSJ</journal-id><journal-id journal-id-type="hwp">spmsj</journal-id><journal-title-group><journal-title>Multiple Sclerosis (Houndmills, Basingstoke, England)</journal-title></journal-title-group><issn pub-type="ppub">1352-4585</issn><issn pub-type="epub">1477-0970</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28381133</article-id><article-id pub-id-type="pmc">5946675</article-id><article-id pub-id-type="doi">10.1177/1352458517704078</article-id><article-id pub-id-type="publisher-id">10.1177_1352458517704078</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Papers</subject></subj-group></article-categories><title-group><article-title>Randomized controlled trial of a home-based palliative approach for
people with severe multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Solari</surname><given-names>Alessandra</given-names></name><xref ref-type="corresp" rid="corresp1-1352458517704078"/><aff id="aff1-1352458517704078">Unit of Neuroepidemiology, Foundation IRCCS
Neurological Institute C. Besta, Milan, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Giordano</surname><given-names>Andrea</given-names></name><aff id="aff2-1352458517704078">Unit of Neuroepidemiology, Foundation IRCCS
Neurological Institute C. Besta, Milan, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Patti</surname><given-names>Francesco</given-names></name><aff id="aff3-1352458517704078">MS Centre, Neurology Clinic, University Hospital
Policlinico Vittorio Emanuele, Catania, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Grasso</surname><given-names>Maria Grazia</given-names></name><aff id="aff4-1352458517704078">Multiple Sclerosis Unit, IRCCS S. Lucia
Foundation, Rome, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Confalonieri</surname><given-names>Paolo</given-names></name><aff id="aff5-1352458517704078">Department of Neuroimmunology and Neuromuscular
Diseases, Foundation IRCCS Neurological Institute C. Besta, Milan,
Italy</aff></contrib><contrib contrib-type="author"><name><surname>Palmisano</surname><given-names>Lucia</given-names></name><aff id="aff6-1352458517704078">National Center for Drug Evaluation and
Research, Istituto Superiore di Sanit&#x000e0;, Rome, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Ponzio</surname><given-names>Michela</given-names></name><aff id="aff7-1352458517704078">Scientific Research Area, Italian Multiple
Sclerosis Foundation (FISM), Genoa, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Borreani</surname><given-names>Claudia</given-names></name><aff id="aff8-1352458517704078">Unit of Clinical Psychology, Foundation IRCCS
Istituto Nazionale per la Cura dei Tumori, Milan, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Rosato</surname><given-names>Rosalba</given-names></name><aff id="aff9-1352458517704078">Department of Psychology, University of Turin,
Turin, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Veronese</surname><given-names>Simone</given-names></name><aff id="aff10-1352458517704078">FARO Charitable Foundation, Turin, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Zaratin</surname><given-names>Paola</given-names></name><aff id="aff11-1352458517704078">Scientific Research Area, Italian Multiple
Sclerosis Foundation (FISM), Genoa, Italy</aff></contrib><contrib contrib-type="author"><name><surname>Battaglia</surname><given-names>Mario Alberto</given-names></name><aff id="aff12-1352458517704078">Department of Life Sciences, University of
Siena, Siena, Italy</aff></contrib><contrib contrib-type="author"><collab>on behalf of the PeNSAMI Project</collab><xref ref-type="author-notes" rid="fn1-1352458517704078">*</xref></contrib></contrib-group><author-notes><corresp id="corresp1-1352458517704078">Unit of Neuroepidemiology, Foundation IRCCS
Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy.
<email>alessandra.solari@istituto-besta.it</email></corresp><fn fn-type="other" id="fn1-1352458517704078"><label>*</label><p>PeNSAMI project investigators are listed in <xref ref-type="app" rid="app1-1352458517704078">Appendix 1</xref>.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><volume>24</volume><issue>5</issue><fpage>663</fpage><lpage>674</lpage><history><date date-type="received"><day>30</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions><abstract><sec id="section1-1352458517704078"><title>Background:</title><p>Evidence on the efficacy of palliative care in persons with severe multiple
sclerosis (MS) is scarce.</p></sec><sec id="section2-1352458517704078"><title>Objective:</title><p>To assess the efficacy of a home-based palliative approach (HPA) for adults
with severe MS and their carers.</p></sec><sec id="section3-1352458517704078"><title>Methods:</title><p>Adults with severe MS-carer dyads were assigned (2:1 ratio) to either HPA or
usual care (UC). At each center, a multi-professional team delivered the
6-month intervention. A blind examiner assessed dyads at baseline, 3&#x02009;months,
and 6&#x02009;months. Primary outcome measures were Palliative care Outcome
Scale-Symptoms-MS (POS-S-MS) and Schedule for the Evaluation of Individual
Quality of Life-Direct Weighting (SEIQoL-DW, not assessed in severely
cognitively compromised patients).</p></sec><sec id="section4-1352458517704078"><title>Results:</title><p>Of 78 dyads randomized, 76 (50&#x02009;HPA, 26&#x02009;UC) were analyzed. Symptom burden
(POS-S-MS) significantly reduced in HPA group compared to UC
(<italic>p</italic>&#x02009;=&#x02009;0.047). Effect size was 0.20 at 3&#x02009;months and 0.32
at 6&#x02009;months, and statistical significance was borderline in per-protocol
analysis (<italic>p</italic>&#x02009;=&#x02009;0.062). Changes in SEIQoL-DW index did not
differ in the two groups, as changes in secondary patient and carer
outcomes.</p></sec><sec id="section5-1352458517704078"><title>Conclusion:</title><p>HPA slightly reduced symptoms burden. We found no evidence of HPA efficacy on
patient quality of life and on secondary outcomes.</p></sec></abstract><kwd-group><kwd>Multiple sclerosis</kwd><kwd>palliative care</kwd><kwd>randomized controlled trial</kwd><kwd>quality of life</kwd><kwd>symptom burden</kwd><kwd>caregivers</kwd></kwd-group><funding-group><award-group id="award1-1352458517704078"><funding-source id="funding1-1352458517704078"><institution-wrap><institution>Fondazione Italiana Sclerosi Multipla</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007366</institution-id></institution-wrap></funding-source><award-id rid="funding1-1352458517704078">2014/S/1</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro" id="section6-1352458517704078"><title>Introduction</title><p>Around 15% of multiple sclerosis (MS) patients have a progressive course from the
outset, and a further 35% develop progressive disease after a variable period with
relapsing disease (secondary progressive MS).<sup><xref rid="bibr1-1352458517704078" ref-type="bibr">1</xref></sup> International, multi-stakeholder initiatives have recently increased the
focus on progressive MS, with the mission to speed up the development of therapies
for people with this challenging disease form, most of whom are severely disabled
for many years.<sup><xref rid="bibr2-1352458517704078" ref-type="bibr">2</xref>,<xref rid="bibr3-1352458517704078" ref-type="bibr">3</xref></sup></p><p>Alignment of treatment with the patient&#x02019;s needs, values, and preferences, a core
element of shared decision-making and palliative care (PC), should be routine aspect
of care of any health professional (HP) and in any care setting. The provision of PC
services, irrespective of diagnosis and illness stage, has been advocated, together
with the development of such services for patients with neurological
diseases.<sup><xref rid="bibr4-1352458517704078" ref-type="bibr">4</xref><xref rid="bibr5-1352458517704078" ref-type="bibr"/>&#x02013;<xref rid="bibr6-1352458517704078" ref-type="bibr">6</xref></sup> In this context
the integration of neurology, PC, and rehabilitation competencies is key, as well as
the individualized care provided by each discipline along the disease
trajectory.<sup><xref rid="bibr7-1352458517704078" ref-type="bibr">7</xref>,<xref rid="bibr8-1352458517704078" ref-type="bibr">8</xref></sup></p><p>A consensus review concluded that there is limited evidence for the provision of PC
for patients with progressive neurological diseases and that further research into
this area of care is urgently needed.<sup><xref rid="bibr9-1352458517704078" ref-type="bibr">9</xref></sup> Two randomized controlled trials (RCTs) have been published on this regard: a
UK trial on 52&#x02009;MS patient-caregiver dyads comparing a 3-month specialist PC service
to standard care found no effect on the primary outcome (emotional, psychological,
and spiritual needs of MS patients). Nevertheless, some symptoms improved and
informal caregiver burden was reduced compared to standard care.<sup><xref rid="bibr5-1352458517704078" ref-type="bibr">5</xref></sup> The other (Neurology-Palliative care (Ne-Pal)) RCT compared a 4-month home
specialist PC service to standard care in 50 people with advanced neurodegenerative
disorders, 36% of whom had MS. The intervention significantly improved patient
quality of life (QoL) and some symptoms compared to standard care; but there was no
effect on caregiver burden.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup></p><p>We performed a multicenter RCT involving adults with severe MS and their carers to
assess the effectiveness of a home-based palliative approach (HPA) added to usual
care (UC). As for the RCTs reported above, we applied the framework for
development/efficacy testing of complex interventions.<sup><xref rid="bibr11-1352458517704078" ref-type="bibr">11</xref></sup> The results of the RCT are presented, except for the economic analysis and
the nested qualitative study, which will be presented in separate papers.</p></sec><sec sec-type="methods" id="section7-1352458517704078"><title>Methods</title><sec id="section8-1352458517704078"><title>Study design and participants</title><p>In this randomized, examiner-blind, controlled study, we recruited patients from
three Italian centers. The protocol was approved by the local ethics committees
and the study was undertaken in accordance with the Declaration of Helsinki.<sup><xref rid="bibr12-1352458517704078" ref-type="bibr">12</xref></sup> The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com">www.controlled-trials.com</ext-link> (ISRCTN73082124).</p><p>Participants were non-institutionalized adults (age&#x02009;&#x02a7e;&#x02009;18&#x02009;years) with severe MS
and their primary carers. Other patient inclusion criteria were primary or
secondary progressive MS,<sup><xref rid="bibr1-1352458517704078" ref-type="bibr">1</xref>,<xref rid="bibr13-1352458517704078" ref-type="bibr">13</xref></sup> Expanded Disability Status Scale (EDSS) score&#x02009;&#x02a7e;&#x02009;8.0,<sup><xref rid="bibr14-1352458517704078" ref-type="bibr">14</xref></sup> complex symptoms,<sup><xref rid="bibr15-1352458517704078" ref-type="bibr">15</xref></sup> and &#x02a7e;2&#x02009;unmet care needs.<sup><xref rid="bibr16-1352458517704078" ref-type="bibr">16</xref></sup> The carer (a family member, relative, or friend of the patient) was his
or her next of kin and was designated by the patient except for patients with
severe cognitive compromise. All patient-carer dyads gave written informed
consent before study enrollment.</p></sec><sec id="section9-1352458517704078"><title>Randomization and masking</title><p>Dyads were randomly assigned (2:1) to receive HPA or UC. Allocation to treatment
groups was done using a third-party, web-based computerized randomization
procedure with stratified minimization for EDSS score (8.0&#x02013;8.5, 9.0&#x02013;9.5),
presence of severe cognitive compromise (clinical judgment), and center (Online
Supplementary Table 1).</p><p>The trial senior statistician (R.R.) was not involved in study conduct. The blind
examiners used a web-based case report form (eCRF), so that visit 1&#x02013;3 data were
available to HPA teams and coordination unit. After visits 2 and 3, examiners
were asked to guess dyad assignment.</p></sec><sec id="section10-1352458517704078"><title>Intervention</title><p>Based on the principles of PC,<sup><xref rid="bibr17-1352458517704078" ref-type="bibr">17</xref></sup> each center had a HPA team consisting of a physician (neurologist or
physiatrist), a nurse (case manager and team leader), a psychologist, and a
social worker. Nurses of the Milan and Rome centers had degrees and worked full
time in PC; the Catania nurse attended a week-long individual training course.
Prior to study start, all team members were trained in the HPA intervention; 3
and 6&#x02009;months after trial initiation they met again to share experiences,
fine-tune the protocol, and discuss difficult cases.</p><p>After a comprehensive assessment of the dyad needs based on direct observation
and on visit 1 information (available via the eCRF), the HPA team defined the
contents of the intervention, involving the dyad and the patient caring
physician (the intervention was not intended to replace existing services).
Subsequently, the team verified program implementation and reviewed it as
necessary. The team was not on call for dyads: in the event of emergencies,
dyads contacted the patient caring physician or emergency medical services. All
team activities were recorded in the PeNSAMI patient study record, which was
kept at the patient&#x02019;s home and available to all HPs/caregivers.</p><p>UC consisted of the health and social services provided by the Italian National
Health Service in the study area. Dyads assigned to UC received the three
examiner visits (visits 1&#x02013;3) and the monthly telephone interviews, but not the
HPA team visits (except visit 0). At the end of the study, dyads who received UC
were offered the HPA.</p></sec><sec id="section11-1352458517704078"><title>Outcomes</title><p>The pre-specified primary endpoints were changes in patient quality of life
(SEIQoL-DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POS-S-MS). The
SEIQoL-DW is administered in an interview in which respondents nominate the five
areas of life that are most important in determining their QoL, and rate the
satisfaction/functioning and weight/importance in each of these areas.<sup><xref rid="bibr18-1352458517704078" ref-type="bibr">18</xref></sup> The SEIQoL-DW index can range from 0 to 100 (best).</p><p>The POS-S-MS (primary outcome measure) and the core POS were developed and
validated for use in PC.<sup><xref rid="bibr18-1352458517704078" ref-type="bibr">18</xref>,<xref rid="bibr19-1352458517704078" ref-type="bibr">19</xref></sup> POS consists of 10 items addressing emotional,
psychological, and spiritual needs, and provision of information and support,
each scored from 0 to 4; POS total score can range from 0 to 40 (worst).
POS-S-MS comprises 20 items relating to MS symptom burden (0 to 4 scale) plus an
open question. Following advice of the POS-S-MS authors, we used the 17 pre-set
items (POS-S-MS total score possible range 0 to 68 (worst)).<sup><xref rid="bibr20-1352458517704078" ref-type="bibr">20</xref></sup> For both core POS (version 1) and POS-S-MS (<ext-link ext-link-type="uri" xlink:href="http://pos-pal.org/maix/">http://pos-pal.org/maix/</ext-link>)
we used the preceding 7&#x02009;days&#x02019; time frame, and caregiver version of the scales in
patients with severe cognitive impairment.</p><p>In addition to core POS, patient secondary outcome measures were the European
Quality of life Five Dimensions (EQ-5D-3L),<sup><xref rid="bibr21-1352458517704078" ref-type="bibr">21</xref></sup> the Hospital Anxiety and Depression Scale (HADS),<sup><xref rid="bibr22-1352458517704078" ref-type="bibr">22</xref></sup> the Functional Independence Measure (FIM),<sup><xref rid="bibr23-1352458517704078" ref-type="bibr">23</xref></sup> and direct and indirect tangible costs (assessed by the MS foundation
Costs Questionnaire, MSCQ).<sup><xref rid="bibr24-1352458517704078" ref-type="bibr">24</xref></sup> Carer outcomes were the Short Form 36 (SF-36),<sup><xref rid="bibr25-1352458517704078" ref-type="bibr">25</xref></sup> the EQ-5D-3L, the HADS, and the Zarit Burden Interview (ZBI).<sup><xref rid="bibr26-1352458517704078" ref-type="bibr">26</xref></sup></p></sec><sec id="section12-1352458517704078"><title>Statistical analysis</title><p>The sample size was based on previous data for POS-S-MS<sup><xref rid="bibr5-1352458517704078" ref-type="bibr">5</xref></sup> and SEIQoL-DW.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup> For the SEIQoL-DW, we were in a more exploratory situation than for the
POS-S-MS, as the available data referred to a mixed population.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup> In addition, we expected that up to 50% of MS patients would have not
been able to complete the SEIQoL-DW (severe cognitive compromise); in these the
only primary endpoint was the POS-S-MS (caregiver version). In view of these
considerations, we purposely considered the two outcomes separately in this
phase II/III RCT, and we set a power of 80% for the SEIQoL-DW and of the 85% for
the POS-S-MS.</p><p>For the POS-S-MS, we calculated that a sample size of 62 patients would yield a
power of 85% to detect a mean score change of &#x02212;0.4 (standard deviation (SD),
0.5) in the HPA group compared to a change of 0.2 (SD, 0.8; null hypothesis) in
the UC group, at an &#x003b1; level of 0.05.<sup><xref rid="bibr5-1352458517704078" ref-type="bibr">5</xref></sup> Assuming 20% dropout, 49 patients were required in the HPA group and 25
patients in the UC group (total sample size 74).</p><p>For the SEIQoL-DW, we calculated that a sample size of 32 patients would yield a
power of 80% to detect a mean score change of 12.1 (SD, 12.8) in the HPA group
compared to a change of &#x02212;7.4 (SD, 19.3) in the UC group, at an &#x003b1; level of 0.05.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup> Assuming 20% dropout, 25 patients were required in the HPA group and 13
in the UC group (total sample size 38).</p><p>All randomly assigned patients were included in the main intention-to-treat
analysis, provided that at least one contact with the team occurred (HPA group).
The average effect of the intervention over time on all outcomes was evaluated
between the two groups using generalized estimating equations (GEE,
repeated-measures analysis of covariance with exchangeable correlation). All
analyses were adjusted for the baseline value of the outcome. Besides
intervention group (HPA, UC) and time visit (3-month, 6-month), all analyses
included as a pre-specified covariate center (Milan, Rome, Catania), as the
intervention was delivered by teams that operated in different socio-cultural
contexts. In addition, for analysis of patient outcomes POS-S-MS, POS, and FIM,
we used the following pre-specified prognostic covariates: presence of severe
cognitive impairment and age (baseline EDSS score was not included in the model
as it was associated with cognitive impairment). For analysis of patient
outcomes SEIQoL-DW and HADS, we used the covariates baseline EDSS score and age.
We also tested for the first-order interaction term center per intervention
group, to assess the homogeneity of the treatment effect across centers. For
analysis of the ZBI total score, we used the covariates and interaction term
reported above (first set of patient outcomes), plus carer&#x02019;s age and sex, and
carer living with the patient.<sup><xref rid="bibr27-1352458517704078" ref-type="bibr">27</xref></sup></p><p>In the main intention-to-treat analysis, missing data were imputed according to
Rubin&#x02019;s Rules (fully conditional specification approach) using the auxiliary
variables age, time visit, center, intervention group, and the baseline value of
each outcome measure. A per-protocol analysis was also done for the primary
outcomes and all secondary outcomes and included only those patients who
accomplished the outcome measures.</p><p>Two-sided <italic>p</italic> values of less than 0.05 were judged to be
significant; <italic>p</italic> values were not adjusted for multiple
comparisons. Analyses were done with Stata (version 13.0) and SAS (version
9.4).</p></sec></sec><sec sec-type="results" id="section13-1352458517704078"><title>Results</title><sec id="section14-1352458517704078"><title>Dyad enrollment and characteristics</title><p>Between January and November 2015, 50 dyads assigned to receive HPA and 26
assigned to receive UC were analyzed (<xref ref-type="fig" rid="fig1-1352458517704078">Figure 1</xref>). <xref ref-type="table" rid="table1-1352458517704078">Table 1</xref> illustrates participant
demographic and clinical characteristics at baseline.</p><fig id="fig1-1352458517704078" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>CONSORT 2010 Flow diagram of the trial.</p><p>HPA: home-based palliative approach; UC: usual care.</p></caption><graphic xlink:href="10.1177_1352458517704078-fig1"/></fig><table-wrap id="table1-1352458517704078" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics of the 76&#x02009;MS patient-carer dyads at baseline, by
allocated group.</p></caption><alternatives><graphic xlink:href="10.1177_1352458517704078-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic<hr/></th><th align="left" rowspan="1" colspan="1">Home-based palliative approach
(<italic>N</italic>&#x02009;=&#x02009;50)</th><th align="left" rowspan="1" colspan="1">Usual care (<italic>N</italic>&#x02009;=&#x02009;26)<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">MS patients</th><th align="left" colspan="2" rowspan="1"><italic>N</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Women</td><td rowspan="1" colspan="1">31 (62)</td><td rowspan="1" colspan="1">12 (46)</td></tr><tr><td rowspan="1" colspan="1">Age (years)<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">60.5&#x02009;&#x000b1;&#x02009;9.7</td><td rowspan="1" colspan="1">56.8&#x02009;&#x000b1;&#x02009;9.5</td></tr><tr><td colspan="3" rowspan="1">Education</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No education completed</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary (5&#x02013;8&#x02009;years)</td><td rowspan="1" colspan="1">19 (38)</td><td rowspan="1" colspan="1">10 (38)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary (12&#x02013;13&#x02009;years)</td><td rowspan="1" colspan="1">20 (40)</td><td rowspan="1" colspan="1">10 (38)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;College/University (14+&#x02009;years)</td><td rowspan="1" colspan="1">10 (20)</td><td rowspan="1" colspan="1">6 (24)</td></tr><tr><td colspan="3" rowspan="1">Occupation</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Employed</td><td rowspan="1" colspan="1">2 (4)</td><td rowspan="1" colspan="1">2 (7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Retired (age)</td><td rowspan="1" colspan="1">9 (18)</td><td rowspan="1" colspan="1">1 (4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unemployed</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Retired (disability)</td><td rowspan="1" colspan="1">39 (78)</td><td rowspan="1" colspan="1">22 (85)</td></tr><tr><td rowspan="1" colspan="1">Age at MS diagnosis (years)<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">37.5&#x02009;&#x000b1;&#x02009;13.8</td><td rowspan="1" colspan="1">35.7&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr><td rowspan="1" colspan="1">Severe cognitive compromise</td><td rowspan="1" colspan="1">9 (18)</td><td rowspan="1" colspan="1">5 (19)</td></tr><tr><td rowspan="1" colspan="1">SEIQoL-DW<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref>,<xref ref-type="table-fn" rid="table-fn5-1352458517704078">3</xref></sup></td><td rowspan="1" colspan="1">61.3&#x02009;&#x000b1;&#x02009;21.5</td><td rowspan="1" colspan="1">59.5&#x02009;&#x000b1;&#x02009;30.0</td></tr><tr><td rowspan="1" colspan="1">POS-S-MS<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">23.7&#x02009;&#x000b1;&#x02009;8.8</td><td rowspan="1" colspan="1">23.9&#x02009;&#x000b1;&#x02009;8.4</td></tr><tr><td rowspan="1" colspan="1">POS<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">12.1&#x02009;&#x000b1;&#x02009;6.8</td><td rowspan="1" colspan="1">12.0&#x02009;&#x000b1;&#x02009;7.2</td></tr><tr><td rowspan="1" colspan="1">EDSS<sup><xref ref-type="table-fn" rid="table-fn4-1352458517704078">2</xref></sup></td><td rowspan="1" colspan="1">8.5 (8.0 to 9.5)</td><td rowspan="1" colspan="1">8.5 (8.0 to 9.5)</td></tr><tr><td rowspan="1" colspan="1">FIM total<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">49.3&#x02009;&#x000b1;&#x02009;16.9</td><td rowspan="1" colspan="1">52.6&#x02009;&#x000b1;&#x02009;22.0</td></tr><tr><td rowspan="1" colspan="1">HADS Anxiety<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref>,<xref ref-type="table-fn" rid="table-fn5-1352458517704078">3</xref></sup></td><td rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;3.9</td><td rowspan="1" colspan="1">6.6&#x02009;&#x000b1;&#x02009;3.9</td></tr><tr><td rowspan="1" colspan="1">Depression<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref>,<xref ref-type="table-fn" rid="table-fn5-1352458517704078">3</xref></sup></td><td rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;4.4</td><td rowspan="1" colspan="1">7.1&#x02009;&#x000b1;&#x02009;3.6</td></tr><tr><th align="left" rowspan="1" colspan="1">Carers</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Women</td><td rowspan="1" colspan="1">31 (62)</td><td rowspan="1" colspan="1">16 (61)</td></tr><tr><td rowspan="1" colspan="1">Age (years)<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">60.1&#x02009;&#x000b1;&#x02009;13.9</td><td rowspan="1" colspan="1">60.8&#x02009;&#x000b1;&#x02009;11.1</td></tr><tr><td colspan="3" rowspan="1">Education</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary (5&#x02013;8&#x02009;years)</td><td rowspan="1" colspan="1">18 (36)</td><td rowspan="1" colspan="1">7 (27)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary (12&#x02013;13&#x02009;years)</td><td rowspan="1" colspan="1">16 (32)</td><td rowspan="1" colspan="1">16 (62)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;College/University (14+&#x02009;years)</td><td rowspan="1" colspan="1">16 (32)</td><td rowspan="1" colspan="1">3 (11)</td></tr><tr><td colspan="3" rowspan="1">Occupation</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Employed/student</td><td rowspan="1" colspan="1">23 (46)</td><td rowspan="1" colspan="1">13 (50)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Retired (age)</td><td rowspan="1" colspan="1">19 (38)</td><td rowspan="1" colspan="1">6 (23)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Housewife</td><td rowspan="1" colspan="1">6 (12)</td><td rowspan="1" colspan="1">7 (27)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unemployed</td><td rowspan="1" colspan="1">2 (4)</td><td rowspan="1" colspan="1">0</td></tr><tr><td colspan="3" rowspan="1">Relation</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Spouse/partner</td><td rowspan="1" colspan="1">25 (50)</td><td rowspan="1" colspan="1">15 (58)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Parent</td><td rowspan="1" colspan="1">8 (16)</td><td rowspan="1" colspan="1">4 (15)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other relative</td><td rowspan="1" colspan="1">7 (14)</td><td rowspan="1" colspan="1">6 (23)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Son/daughter</td><td rowspan="1" colspan="1">8 (16)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Paid caregiver</td><td rowspan="1" colspan="1">2 (4)</td><td rowspan="1" colspan="1">1 (4)</td></tr><tr><td rowspan="1" colspan="1">ZBI total score<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">35.9&#x02009;&#x000b1;&#x02009;15.3</td><td rowspan="1" colspan="1">34.1&#x02009;&#x000b1;&#x02009;12.5</td></tr><tr><td rowspan="1" colspan="1">SF-36 Physical Composite<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref>,<xref ref-type="table-fn" rid="table-fn6-1352458517704078">4</xref></sup></td><td rowspan="1" colspan="1">44.4&#x02009;&#x000b1;&#x02009;10.9</td><td rowspan="1" colspan="1">43.2&#x02009;&#x000b1;&#x02009;11.8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mental Composite<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref>,<xref ref-type="table-fn" rid="table-fn6-1352458517704078">4</xref></sup></td><td rowspan="1" colspan="1">38.4&#x02009;&#x000b1;&#x02009;9.1</td><td rowspan="1" colspan="1">43.6&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr><td rowspan="1" colspan="1">HADS Anxiety<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">9.3&#x02009;&#x000b1;&#x02009;4.0</td><td rowspan="1" colspan="1">8.0&#x02009;&#x000b1;&#x02009;4.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Depression<sup><xref ref-type="table-fn" rid="table-fn3-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">7.1&#x02009;&#x000b1;&#x02009;4.1</td><td rowspan="1" colspan="1">7.0&#x02009;&#x000b1;&#x02009;5.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1352458517704078"><p>EDSS: Expanded Disability Status Scale; FIM: Functional Independence
Measure; HADS: Hospital Anxiety and Depression Scale; MS: multiple
sclerosis; POS: Palliative care Outcome Scale; POS-S-MS: Palliative
care Outcome Scale-Symptoms-Multiple Sclerosis; SEIQoL-DW: Schedule
for the Evaluation of Individual Quality of Life-Direct Weighting;
SF-36: Short Form 36; ZBI: Zarit Burden Interview.</p></fn><fn id="table-fn2-1352458517704078"><p>There were no significant differences between the groups except for
carer education (<italic>p</italic>&#x02009;=&#x02009;0.04) and for SF-36 Mental
Composite (<italic>p</italic>&#x02009;=&#x02009;0.02).</p></fn><fn id="table-fn3-1352458517704078"><label>1</label><p>Mean&#x02009;&#x000b1;&#x02009;standard deviation.</p></fn><fn id="table-fn4-1352458517704078"><label>2</label><p>Median (range).</p></fn><fn id="table-fn5-1352458517704078"><label>3</label><p>Assessed in 41 (82%) home-based palliative approach and 21 (81%)
usual care patients who had no severe cognitive impairment.</p></fn><fn id="table-fn6-1352458517704078"><label>4</label><p>For five home-based palliative approach and two usual care carers,
Physical and Mental Composites were not calculated, in all cases due
to missing items.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section15-1352458517704078"><title>HPA team activities</title><p>Overall there were 360 home visits, 269 (75%) by one HP, 85 (24%) by two, and six
(2%) by three or four HPs. On average, dyads received 4.9 home visits in the
first 3&#x02009;months and 2.8 in the second 3&#x02009;months. The nurse (team leader) performed
152 visits (33%), followed by the psychologist (25%), the physician (25%), and
the social worker (17%). Figures were well balanced across centers (<xref ref-type="table" rid="table2-1352458517704078">Table 2</xref>) except for
the number of visits performed by two or more HPs (Milan 4%, Rome 14%, Catania
51%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Time from randomization to HPA team
assessment was shorter in Catania (median 8&#x02009;days) compared to Milan (11&#x02009;days)
and Rome (12.5&#x02009;days; <italic>p</italic>&#x02009;=&#x02009;0.11).</p><table-wrap id="table2-1352458517704078" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Home-based palliative approach (HPA) team activities in the three
participating centers.</p></caption><alternatives><graphic xlink:href="10.1177_1352458517704078-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">Milan<hr/></th><th align="left" rowspan="1" colspan="1">Rome</th><th align="left" rowspan="1" colspan="1">Catania</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1"><italic>N</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Dyads assessed</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">Dyads who completed the first 3&#x02009;months</td><td rowspan="1" colspan="1">16 (100)</td><td rowspan="1" colspan="1">13 (87)</td><td rowspan="1" colspan="1">18 (95)</td></tr><tr><td rowspan="1" colspan="1">Dyads who completed the second 3&#x02009;months</td><td rowspan="1" colspan="1">16 (100)</td><td rowspan="1" colspan="1">12 (80)</td><td rowspan="1" colspan="1">17 (89)</td></tr><tr><td rowspan="1" colspan="1">Time from randomization to HPA team assessment (days)<sup><xref ref-type="table-fn" rid="table-fn8-1352458517704078">1</xref></sup></td><td rowspan="1" colspan="1">11.4, 11.0 (4 to 29)</td><td rowspan="1" colspan="1">13.5, 12.5 (3 to 28)</td><td rowspan="1" colspan="1">9.3, 8.0 (2 to 25)</td></tr><tr><td rowspan="1" colspan="1">Dyads assessed&#x02009;&#x0003e;&#x02009;14&#x02009;days from randomization</td><td rowspan="1" colspan="1">3 (20)</td><td rowspan="1" colspan="1">5 (36)</td><td rowspan="1" colspan="1">3 (16)</td></tr><tr><td rowspan="1" colspan="1">HPA team visits, months 1&#x02013;3</td><td rowspan="1" colspan="1">79 (4.9&#x02009;per dyad)</td><td rowspan="1" colspan="1">64 (4.9&#x02009;per dyad)</td><td rowspan="1" colspan="1">89 (4.9&#x02009;per dyad)</td></tr><tr><td rowspan="1" colspan="1">HPA team visits, months 4&#x02013;6</td><td rowspan="1" colspan="1">46 (2.9&#x02009;per dyad)</td><td rowspan="1" colspan="1">28 (2.3&#x02009;per dyad)</td><td rowspan="1" colspan="1">54 (3.2&#x02009;per dyad)</td></tr><tr><td colspan="4" rowspan="1">Number of professionals involved in the home
visits</td></tr><tr><td rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">120 (96)</td><td rowspan="1" colspan="1">79 (86)</td><td rowspan="1" colspan="1">70 (49)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">5 (4)</td><td rowspan="1" colspan="1">13 (14)</td><td rowspan="1" colspan="1">67 (47)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3, 4</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">6 (4)</td></tr><tr><td colspan="4" rowspan="1">Type of health professional</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Nurse (team leader)</td><td rowspan="1" colspan="1">38 (29)</td><td rowspan="1" colspan="1">36 (34)</td><td rowspan="1" colspan="1">78 (34)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Psychologist</td><td rowspan="1" colspan="1">38 (29)</td><td rowspan="1" colspan="1">26 (25)</td><td rowspan="1" colspan="1">54 (24)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Physician</td><td rowspan="1" colspan="1">24 (18)</td><td rowspan="1" colspan="1">25 (24)</td><td rowspan="1" colspan="1">66 (29)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Social worker</td><td rowspan="1" colspan="1">30 (23)</td><td rowspan="1" colspan="1">18 (17)</td><td rowspan="1" colspan="1">29 (13)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn7-1352458517704078"><p>All activities (except for HPA team meetings) were performed at
patient&#x02019;s home.</p></fn><fn id="table-fn8-1352458517704078"><label>1</label><p>Mean, median (range).</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="fig" rid="fig2-1352458517704078">Figure 2</xref> reports the
pre-specified care needs<sup><xref rid="bibr16-1352458517704078" ref-type="bibr">16</xref></sup> addressed by the HPA teams, and those fulfilled at the end of the
intervention, based on team reports. The most addressed care needs belonged to
the domain &#x0201c;managing everyday life&#x0201d; (38%), followed by &#x0201c;organization&#x0201d; (34%) and
&#x0201c;psychosocial&#x0201d; (27%). A partial or complete fulfillment was reported for most
&#x0201c;managing everyday life&#x0201d; needs (97%), but for &#x0201c;organization&#x0201d; (73%) and
&#x0201c;psychosocial&#x0201d; (72%) dimensions fulfillment was lower, particularly for &#x0201c;access
to services&#x0201d; and &#x0201c;emotional wellbeing&#x0201d; categories. These patterns appeared quite
similar across the centers (Online Supplementary Figure). In no instance
spiritual needs were identified (or addressed). Discussion about advance care
directives and end-of-life decisions was reported for two patients.</p><fig id="fig2-1352458517704078" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The care needs addressed (dark gray, overall <italic>n</italic>&#x02009;=&#x02009;338)
and fulfilled (light gray, <italic>n</italic>&#x02009;=&#x02009;276) as reported by the
home-based palliative approach (HPA) teams. Care needs are grouped into
11 pre-set categories and 3 domains.<sup><xref rid="bibr16-1352458517704078" ref-type="bibr">16</xref></sup></p></caption><graphic xlink:href="10.1177_1352458517704078-fig2"/></fig></sec><sec id="section16-1352458517704078"><title>Primary outcomes</title><p>Mean change in POS-S-MS score from baseline to 3&#x02009;months was 1.1 (95% confidence
interval (CI), &#x02212;0.5 to 2.7) in the HPA group and &#x02212;0.2 (95% CI, &#x02212;2.9 to 2.6) in
the UC group, with a mean between-group difference of 1.3 (95% CI, &#x02212;1.7 to 4.2),
and a Cohen&#x02019;s <italic>d</italic> effect size (ES) of 0.20. Mean change in
POS-S-MS from baseline to 6&#x02009;months was 2.3 (95% CI, 0.4 to 4.1) in the HPA group
and 0.3 (&#x02212;2.0 to 2.6) in the UC group, with a mean between-group difference of
1.9 (95% CI, &#x02212;1.1 to 5.0) and an ES of 0.32 (<xref ref-type="fig" rid="fig3-1352458517704078">Figure 3</xref>). There were no data
missing/imputed at baseline; data of three HPA patients were missing at 3&#x02009;months
and of five HPA patients at 6&#x02009;months. The pre-specified multivariate analysis is
reported in <xref ref-type="table" rid="table3-1352458517704078">Table 3</xref>:
HPA significantly reduced symptom burden (<italic>p</italic>&#x02009;=&#x02009;0.047), and there
was no interaction between intervention and center (<italic>p</italic>&#x02009;=&#x02009;0.62).
In the per-protocol analysis (Online Supplementary Table 2), the HPA effect on
POS-S-MS was of borderline statistical significance
(<italic>p</italic>&#x02009;=&#x02009;0.062).</p><fig id="fig3-1352458517704078" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Change in the two primary outcome measures Palliative care Outcome
Scale-Symptoms-Multiple Sclerosis (POS-S-MS) and Schedule for the
Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) by
intervention group (intention-to-treat data). Point estimates and
confidence intervals (CIs) are from the raw data.</p><p>HPA: home-based palliative approach; UC: usual care.</p></caption><graphic xlink:href="10.1177_1352458517704078-fig3"/></fig><table-wrap id="table3-1352458517704078" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Generalized estimating equation models (intention-to-treat analysis) of
the two primary outcomes.</p></caption><alternatives><graphic xlink:href="10.1177_1352458517704078-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Covariate</th><th align="left" rowspan="1" colspan="1">Coefficient (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Palliative care Outcome Scale-Symptoms-Multiple
Sclerosis (POS-S-MS) score</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HPA (vs UC)</td><td rowspan="1" colspan="1">&#x02212;2.10 (&#x02212;4.18 to 0.03)</td><td rowspan="1" colspan="1">0.047</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Rome (vs Milan)</td><td rowspan="1" colspan="1">1.04 (&#x02212;1.45 to 3.52)</td><td rowspan="1" colspan="1">0.41</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Catania (vs Milan)</td><td rowspan="1" colspan="1">0.82 (&#x02212;1.58 to 3.21)</td><td rowspan="1" colspan="1">0.50</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Age (years)</td><td rowspan="1" colspan="1">0.12 (0.01 to 0.22)</td><td rowspan="1" colspan="1">0.026</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Severe cognitive compromise</td><td rowspan="1" colspan="1">3.54 (0.83 to 6.26)</td><td rowspan="1" colspan="1">0.010</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Time visit (6-month vs 3-month)</td><td rowspan="1" colspan="1">&#x02212;0.91 (&#x02212;2.33 to 0.50)</td><td rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;POS-S-MS score at baseline</td><td rowspan="1" colspan="1">0.63 (0.50 to 0.76)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Intervention group&#x02009;&#x000d7;&#x02009;center</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.62</td></tr><tr><td colspan="3" rowspan="1">Schedule for the Evaluation of Individual
Quality of Life-Direct Weighting (SEIQoL-DW) index</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HPA (vs UC)</td><td rowspan="1" colspan="1">&#x02212;2.49 (&#x02212;11.15 to 6.17)</td><td rowspan="1" colspan="1">0.57</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Rome (vs Milan)</td><td rowspan="1" colspan="1">&#x02212;3.82 (&#x02212;15.09 to 7.45)</td><td rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Catania (vs Milan)</td><td rowspan="1" colspan="1">4.58 (&#x02212;5.97 to 15.13)</td><td rowspan="1" colspan="1">0.39</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Age (years)</td><td rowspan="1" colspan="1">&#x02212;0.11 (&#x02212;0.55 to 0.33)</td><td rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EDSS score at baseline</td><td rowspan="1" colspan="1">&#x02212;7.11 (&#x02212;19.00 to 4.78)</td><td rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Time visit (6-month vs 3-month)</td><td rowspan="1" colspan="1">&#x02212;0.98 (&#x02212;6.66 to 4.70)</td><td rowspan="1" colspan="1">0.73</td></tr><tr><td rowspan="1" colspan="1">&#x02003;SEIQoL-DW index at baseline</td><td rowspan="1" colspan="1">0.37 (0.19 to 0.54)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Intervention group&#x02009;&#x000d7;&#x02009;center</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.70</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn9-1352458517704078"><p>EDSS: Expanded Disability Status Scale; HPA: home-based palliative
approach; UC: usual care; CI: confidence interval.</p></fn><fn id="table-fn10-1352458517704078"><p>Treatment effect by center is reported when the interaction term is
statistically significant.</p></fn></table-wrap-foot></table-wrap><p>The SEIQoL-DW interview was administered to 62 patients (82%; 41&#x02009;HPA, 21&#x02009;UC)
without severe cognitive impairment. Mean change in SEIQoL-DW index score from
baseline to 3&#x02009;months was &#x02212;0.9 (95% CI, &#x02212;6.8 to 5.1) in the HPA group and &#x02212;3.7
(&#x02212;17.6 to 10.3) in the UC group, with a mean between-group difference of 2.8
(95% CI, &#x02212;12.2 to 17.8; ES, 0.11). Mean change in SEIQoL-DW from baseline to
6&#x02009;months was 0.8 (95% CI, &#x02212;5.3 to 6.9) in the HPA group and &#x02212;4.0 (&#x02212;21.1 to 13.1)
in the UC group, with a mean between-group difference of 4.8 (95% CI, &#x02212;13.2 to
22.7; ES, 0.10; <xref ref-type="fig" rid="fig3-1352458517704078">Figure
3</xref>). There were no data missing/imputed at baseline; data of four HPA
patients were missing at both 3 and 6&#x02009;months. In the pre-specified multivariate
analysis, HPA had no significant effect on the primary outcome
(<italic>p</italic>&#x02009;=&#x02009;0.57), and there was no interaction between
intervention and center (<italic>p</italic>&#x02009;=&#x02009;0.70; <xref ref-type="table" rid="table3-1352458517704078">Table 3</xref>). Findings from the
per-protocol analysis matched those of the main analysis (Online Supplementary
Table 2).</p></sec><sec id="section17-1352458517704078"><title>Serious adverse events and attrition</title><p>There were 22 serious adverse events (<xref ref-type="table" rid="table4-1352458517704078">Table 4</xref>) in 20 patients, 15 events in
13 patients on HPA (30%), and 7 events in 7 patients on UC (27%;
<italic>p</italic>&#x02009;=&#x02009;0.78). Three HPA patients died, all deaths were deemed
to be unrelated to the intervention. Three dyads discontinued the intervention,
one in the HPA group and two in the UC group (<xref ref-type="fig" rid="fig1-1352458517704078">Figure 1</xref>); one HPA dyad completed the
intervention but did not perform visit 3.</p><table-wrap id="table4-1352458517704078" orientation="portrait" position="float"><label>Table 4.</label><caption><p>The 22 serious adverse events (20 patients) listed by report date
(day/month/year).</p></caption><alternatives><graphic xlink:href="10.1177_1352458517704078-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Patient code</th><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Baseline EDSS</th><th align="left" rowspan="1" colspan="1">Randomization date</th><th align="left" rowspan="1" colspan="1">Report date</th><th align="left" rowspan="1" colspan="1">Event date</th><th align="left" rowspan="1" colspan="1">Weeks from randomization</th><th align="left" rowspan="1" colspan="1">Event description</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">0315</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">9.0</td><td rowspan="1" colspan="1">08/04/15</td><td rowspan="1" colspan="1">11/05/15</td><td rowspan="1" colspan="1">05/05/15</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Ab-ingestis pneumonia</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0311</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">07/03/15</td><td rowspan="1" colspan="1">18/05/15</td><td rowspan="1" colspan="1">06/04/15</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Generalized anxiety</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0211</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">13/05/15</td><td rowspan="1" colspan="1">26/05/15</td><td rowspan="1" colspan="1">23/05/15</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Cardiac failure</td><td rowspan="1" colspan="1"><italic>Death</italic> (13&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0314</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">22/03/15</td><td rowspan="1" colspan="1">27/05/15</td><td rowspan="1" colspan="1">11/05/15</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Acute respiratory failure</td><td rowspan="1" colspan="1"><italic>Death</italic> (emergency ward)</td></tr><tr><td rowspan="1" colspan="1">0112</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1">23/03/15</td><td rowspan="1" colspan="1">28/05/15</td><td rowspan="1" colspan="1">12/05/15</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Breathing difficulty</td><td rowspan="1" colspan="1">Resolved (21&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0203</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">03/03/15</td><td rowspan="1" colspan="1">03/06/15</td><td rowspan="1" colspan="1">27/05/15</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Urine retention</td><td rowspan="1" colspan="1">Resolved (6&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0111</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">9.0</td><td rowspan="1" colspan="1">17/03/15</td><td rowspan="1" colspan="1">16/06/15</td><td rowspan="1" colspan="1">08/05/15</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Anarthria</td><td rowspan="1" colspan="1">Resolved (3&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0305</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">24/02/15</td><td rowspan="1" colspan="1">29/06/15</td><td rowspan="1" colspan="1">11/06/15</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Contact dermatitis</td><td rowspan="1" colspan="1">Resolved (7&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0321</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1">30/05/15</td><td rowspan="1" colspan="1">20/07/15</td><td rowspan="1" colspan="1">10/07/15</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Dysphagia</td><td rowspan="1" colspan="1">Gastrostomy tube placement (3&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0308</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">14/03/15</td><td rowspan="1" colspan="1">12/08/15</td><td rowspan="1" colspan="1">07/08/15</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Breathing difficulty, vomiting</td><td rowspan="1" colspan="1">Resolved (1&#x02009;day H)</td></tr><tr><td rowspan="1" colspan="1">0318</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">02/05/15</td><td rowspan="1" colspan="1">12/08/15</td><td rowspan="1" colspan="1">07/08/15</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Cardiac failure</td><td rowspan="1" colspan="1"><italic>Death</italic> (home)</td></tr><tr><td rowspan="1" colspan="1">0203</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">03/03/15</td><td rowspan="1" colspan="1">04/09/15</td><td rowspan="1" colspan="1">30/08/15</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Bladder catheter malfunctioning</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0213</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">9.0</td><td rowspan="1" colspan="1">04/06/15</td><td rowspan="1" colspan="1">14/10/15</td><td rowspan="1" colspan="1">29/09/15</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Fever, breathing difficulty</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0322</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">9.0</td><td rowspan="1" colspan="1">30/05/15</td><td rowspan="1" colspan="1">09/10/15</td><td rowspan="1" colspan="1">02/09/15</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Acute urine retention/infection</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0218</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">30/07/15</td><td rowspan="1" colspan="1">07/01/16</td><td rowspan="1" colspan="1">26/12/15</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Arrhythmia</td><td rowspan="1" colspan="1">Resolved (3&#x02009;days H)</td></tr><tr><td rowspan="1" colspan="1">0328</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">25/07/15</td><td rowspan="1" colspan="1">16/01/16</td><td rowspan="1" colspan="1">22/12/15</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Necrotizing fasciitis</td><td rowspan="1" colspan="1">Day surgery (discharged)</td></tr><tr><td rowspan="1" colspan="1">0136</td><td rowspan="1" colspan="1">UC</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">28/10/15</td><td rowspan="1" colspan="1">20/01/16</td><td rowspan="1" colspan="1">11/12/15</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Traumatic wound</td><td rowspan="1" colspan="1">Resolved (wound suture)</td></tr><tr><td rowspan="1" colspan="1">0220</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">9.0</td><td rowspan="1" colspan="1">02/10/15</td><td rowspan="1" colspan="1">13/02/16</td><td rowspan="1" colspan="1">23/01/16</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Fever, macrohematuria</td><td rowspan="1" colspan="1">Resolved (1&#x02009;day H)</td></tr><tr><td rowspan="1" colspan="1">0137</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">06/11/15</td><td rowspan="1" colspan="1">04/03/16</td><td rowspan="1" colspan="1">23/02/16</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Difficulty with bladder catheter removal</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1">0138</td><td rowspan="1" colspan="1">HPA</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">18/11/15</td><td rowspan="1" colspan="1">21/03/16</td><td rowspan="1" colspan="1">19/02/16</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Acute urine retention, constipation</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">22/02/16</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Acute urine retention, abdominalgia</td><td rowspan="1" colspan="1">Resolved (discharged)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">01/03/16</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Fever, bronchitis, macrohematuria</td><td rowspan="1" colspan="1">Resolved (1&#x02009;day H)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn11-1352458517704078"><p>EDSS: Expanded Disability Status Scale; H: hospitalization; HPA:
home-based palliative approach; UC: usual care.</p></fn><fn id="table-fn12-1352458517704078"><p>All were emergency ward admissions except the event of patient code
0318 (home death).</p></fn></table-wrap-foot></table-wrap></sec><sec id="section18-1352458517704078"><title>Other patient outcomes</title><p>We found no significant difference between intervention groups for change at 3
and 6&#x02009;months in POS, HADS Anxiety and Depression, and FIM total score (Online
Supplementary Table 3). Two patients with baseline EDSS 8.0 worsened to EDSS 8.5
at 3- and 6-month visits (one from each intervention group), the other remained
unchanged (data not shown). Per-protocol analysis of secondary patient outcomes
are reported in the Online Supplementary Table 2.</p></sec><sec id="section19-1352458517704078"><title>Caregiver burden and other carer outcomes</title><p>Mean change in ZBI score from baseline to 3&#x02009;months was 1.1 (95% CI, &#x02212;1.7 to 3.9)
in the HPA group and &#x02212;0.5 (&#x02212;4.1 to 3.2) in the UC group, with a mean
between-group difference of 1.6 (95% CI, &#x02212;3.1 to 6.2; ES, 0.16). Mean change
from baseline to 6 months was 0.2 (95% CI, &#x02212;2.8 to 3.2) in the HPA group and 1.7
(&#x02212;1.1 to 4.5) in the UC group, with a mean between-group difference of &#x02212;1.5 (95%
CI, &#x02212;6.1 to 3.1; ES, 0.16). There was no effect of HPA on ZBI score
(<italic>p</italic>&#x02009;=&#x02009;0.83), or interaction between intervention and center
(<italic>p</italic>&#x02009;=&#x02009;0.20; Online Supplementary Table 3). Per-protocol
analysis findings matched those of the main analysis (Online Supplementary Table
4).</p></sec><sec id="section20-1352458517704078"><title>Examiner&#x02019;s masking</title><p>At visit 2, examiners guessed dyad assignment correctly in 12/73 (17%),
incorrectly in 6 (8%), and answered &#x0201c;don&#x02019;t know&#x0201d; in 55 (75%). Figures at visit 3
were 14% for correct, 7% for incorrect, and 79% for &#x0201c;don&#x02019;t know&#x0201d; answers.
Examiners guessed the correct assignment in both visits in four HPA dyads (9%)
and one UC dyad (4%).</p></sec></sec><sec sec-type="discussion" id="section21-1352458517704078"><title>Discussion</title><p>In this 6-month RCT in severely affected MS adults, an HPA reduced symptom burden as
assessed using the multidimensional POS-S-MS (primary outcome measure). The size of
HPA effect was small, manifested at the end of the study, and the statistical
significance was borderline. Three patients died during the study, all belonging to
HPA group. The independent data and safety monitoring committee confirmed the center
principal investigator judgment that these deaths were unrelated to the
intervention. One further patient died immediately after baseline visit and the day
before randomization, and one in the trial screening phase (<xref ref-type="fig" rid="fig1-1352458517704078">Figure 1</xref>).</p><p>Reduction of symptom burden was in line with evidence from the UK trial, which found
improvement in a subset of five POS-S-MS symptoms (pain, nausea, vomiting, mouth
problems, and sleeping difficulty).<sup><xref rid="bibr5-1352458517704078" ref-type="bibr">5</xref></sup> We identified no evidence of efficacy of the intervention for the SEIQoL-DW
(primary outcome measure), or for secondary patient (POS, HADS, FIM), and carer
outcomes (22-item ZBI, SF-36, HADS). Findings for caregiver burden were at odds with
the UK trial, which found a significant improvement in those carers (13/26 in the PC
group and 17/26 in the standard care group) who completed the 12-item ZBI.<sup><xref rid="bibr5-1352458517704078" ref-type="bibr">5</xref></sup> It should be noted that findings on caregiver burden in PC interventions are
conflicting, as highlighted by a recent systematic review and meta-analysis.<sup><xref rid="bibr28-1352458517704078" ref-type="bibr">28</xref></sup></p><p>At main difference with the UK and Ne-Pal trials was that in PeNSAMI the teams
involved did not originate from PC services, and this was not a specialist PC intervention.<sup><xref rid="bibr29-1352458517704078" ref-type="bibr">29</xref></sup> The three HPA multi-professional teams were led by a nurse who received
higher specialist training and worked full time in PC (Milan and Rome) or had
received PC training for the trial and worked full time in MS rehabilitation
(Catania); the physicians (one neurologist and two neurologists and physiatrists)
and the other professionals were MS experts. The clinical characteristics of our
patients were similar to those of the UK trial, but Ne-Pal included patients with
other neurological conditions, and excluded patients with severe cognitive compromise.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup> As in the UK trial, the HPA teams addressed the identified needs of the dyads
indirectly, by activating existing services or bringing them to the attention of the
dyads, which was a major study challenge due to the fragmentation of care and silos
working style of services.<sup><xref rid="bibr15-1352458517704078" ref-type="bibr">15</xref>,<xref rid="bibr30-1352458517704078" ref-type="bibr">30</xref></sup> This may have impacted the response to the intervention, which
we originally hypothesized at 3&#x02009;months. It is thus possible that as for the
reduction in symptom burden (POS-S-MS) which manifested at 6-month visit (<xref ref-type="fig" rid="fig3-1352458517704078">Figure 3</xref>), the time of HPA
care was insufficient to produce an effect on most outcome measures. Data from team
records also documented a difficulty in HPA goal achievement especially for
psychosocial and organizational issues, while for symptom management and activities
of daily living needs were at least partially met in the 6-month time frame (<xref ref-type="fig" rid="fig2-1352458517704078">Figure 2</xref>). These issues also
emerged from the focus group of the HPA teams conducted at the end of the trial
(Online Supplementary Box), and should be carefully considered in the design of
future PC trials for MS patients, which should at best match with both service
activation and the MS disease trajectory.</p><p>Other differences with the two published RCTs which inspired our study are the
adoption of a multicenter design and an examiner-blind design (the nature of the
intervention prevented us from blinding patients and carers to their allocated
group). The latter made more complex (and burdensome) the study procedures: the
SEIQoL-DW interview was not administered by the HPA team (team members could only
access SEIQoL-DW data of the patient via the eCRF), and participants had sometimes
difficulty in distinguishing HPA team and examiner roles. In addition, the
examiner&#x02019;s visits (particularly the SEIQoL-DW interview) and the monthly telephone
interviews may have produced some non-specific effect in the UC group, which might
have moderated the occurrence of performance bias.<sup><xref rid="bibr31-1352458517704078" ref-type="bibr">31</xref></sup> However, an examiner-blind design improves the quality of the study by
preventing ascertainment bias.<sup><xref rid="bibr31-1352458517704078" ref-type="bibr">31</xref></sup> Inter-rater reliability (in outcome ascertainment) was a minor issue as in
Milan and Catania outcome measures were obtained by the center&#x02019;s main examiner only,
and in Rome both trained examiners (main and backup) operated. We met our
recruitment and retention targets, and missing data on both patient and carer
outcomes were &#x0003c;10%&#x02014;well below our pre-specified hypothesis,<sup><xref rid="bibr12-1352458517704078" ref-type="bibr">12</xref></sup> and data of RCTs on PC.<sup><xref rid="bibr28-1352458517704078" ref-type="bibr">28</xref>,<xref rid="bibr32-1352458517704078" ref-type="bibr">32</xref></sup></p><p>It is essential to have QOL as a primary outcome measure for a PC intervention.<sup><xref rid="bibr17-1352458517704078" ref-type="bibr">17</xref></sup> We chose the SEIQoL-DW interview as it is an individualized tool, preventing
patient exposure to non-pertinent or frustrating items, and the oversight of
significant QOL dimensions. Ne-Pal findings provided evidence of the feasibility of
SEIQoL-DW administration in this disabled patient population and good scale responsiveness.<sup><xref rid="bibr10-1352458517704078" ref-type="bibr">10</xref></sup> However, in view of the PeNSAMI trial experience, this instrument may have a
higher potential in the hands of the treating professionals (here the HPA team), as
it can be used to elucidate patient values and priorities, and thus facilitate the
setting of goals that are aligned to such values.<sup><xref rid="bibr33-1352458517704078" ref-type="bibr">33</xref></sup></p><p>To conclude, PeNSAMI trial showed that 6-month HPA slightly reduces MS symptom
burden, but did not produce evidence of an effect on patient QOL, or on the
multifaceted patient-carer needs. Moreover, our findings suggest that a PC
intervention for patients with severe MS may need to be over a longer period than
6&#x02009;months. The trial was designed and conducted to minimize the risk of bias, at the
expense of some burden for patients, carers, and HPs. The analysis of the
qualitative study nested in the RCT, by addressing the living experiences of
participants, will supplement trial findings, identify the strengths and challenges
of the intervention, and contribute to improve intervention&#x02019;s contents, processes,
and timing.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_box.pdf" orientation="portrait" id="d35e1904" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_figure.pdf" orientation="portrait" id="d35e1909" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_table_1.pdf" orientation="portrait" id="d35e1914" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_table_2.pdf" orientation="portrait" id="d35e1919" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_table_3.pdf" orientation="portrait" id="d35e1924" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MSJ704078_supplementary_table_4.pdf" orientation="portrait" id="d35e1929" position="anchor"/></supplementary-material></sec></body><back><ack><p>We thank all of the MS patients and carers who participated in the study. We also
thank Professors Diego Centonze and Marco Salvetti; Drs Milena De Riz, Giancarlo Di
Battista, Claudio Gasperini, Alessandra Protti, and Marco Rovaris; and the local
sections of the Italian Multiple Sclerosis Society in Milan, Rome, and Catania, for
their help with dyad recruitment, and the POS team for their advice on the POS-S-MS
scale. Trial registration number: ISRCTN73082124.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: A.S. has been a
board member of Biogen Idec, Merck Serono and Novartis and has received speaker
honoraria from Genzyme, Merck Serono, and Excemed. F.P. received honoraria for
speaking activities from Bayer Schering, Biogen Idec, Merck Serono, Novartis,
and Sanofi Aventis. He has served as advisory board member of the following
companies: Bayer Schering, Biogen Idec, Merck Serono, and Novartis. M.G.G. has
received research funding from Merck Serono and consulting and speaking fees
from Biogen Idec. P.C. has been a board member of Biogen Idec, received travel
grants from Sanofi Aventis, Biogen Dompe, and Merck Serono. P.Z. and M.A.B. are
board members of the Fondazione Italiana Sclerosi Multipla (charitable
organization). All other authors declare that they have no competing
interests.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The Fondazione
Italiana Sclerosi Multipla (FISM) funded the trial (Grant No. 2014/S/1 to
A.S.).</p></fn></fn-group><app-group><app id="app1-1352458517704078"><title>Appendix 1</title><sec id="section22-1352458517704078"><title>PeNSAMI project investigators</title><p>Steering Committee: R Amadeo: <italic>Italian Multiple Sclerosis Society
(AISM)</italic>; A Giordano, M Ponzio, MG Grasso, A Lugaresi, F Patti; G
Martino: <italic>Italian Multiple Sclerosis Society (AISM), Genoa</italic>;
L Palmisano: <italic>Istituto Superiore di Sanit&#x000e0;, Rome</italic>; S
Veronese, P Zaratin, MA Battaglia, and A Solari.</p><p>Data Management and Analysis Committee: A Giordano; E Pagano (cost analysis):
<italic>Unit of Cancer Epidemiology, &#x0201c;Citt&#x000e0; della Salute e della
Scienza&#x0201d; University Hospital of Turin and CPO Piemonte, Turin</italic>;
D Radice (statistician): <italic>Division of Epidemiology and Biostatistics,
European Institute of Oncology, Milan</italic>; M Farinotti, G Ferrari,
A Solari; R Rosato (statistician): <italic>Department of Psychology,
University of Turin</italic>.</p><p>Independent Data and Safety Monitoring Committee: DJ Oliver (Chair):
<italic>University of Kent, Rochester, Kent, UK</italic>; E Pucci:
<italic>Neurology Unit, Ospedale Provinciale di Macerata,
Macerata</italic>; L Tesio: <italic>Department of &#x02009;Biomedical Sciences
for Health, University of Milan, Milan; The Istituto Auxologico
Italiano, IRCCS, Milan</italic>.</p><p>Qualitative Analysis Panel: E Bianchi; S Cilia: <italic>University Hospital
Policlinico Vittorio Emanuele, Catania</italic>; S Cipollari:
<italic>IRCCS S Lucia Foundation, Rome</italic>; E Pietrolongo, M
Giuntoli, and C Borreani.</p><p>Literature Review Panel: MG Grasso, L Palmisano, A Fittipaldo, and A
Giordano.</p><p>Intervention Panel: C Cugno, R Causarano; P Morino: &#x0201c;<italic>Ex Convento
delle Oblate&#x0201d; Hospice, Local Health Unit of Florence, Florence</italic>;
S Veronese.</p><p>Enrolling Centers and Investigators: <italic>Foundation IRCCS Neurological
Institute C Besta, Milan</italic>: P Confalonieri, E Rossetti, AM
Giovannetti, V Torri Clerici, A Totis, A Campanella, M Farinotti, A
Fittipaldo, G Ferrari, R Mantegazza, A Giordano, and A Solari; <italic>IRCCS
S Lucia Foundation, Rome</italic>: MG Grasso, MC Stefanelli, I Rossi, L
Tucci, F Ippoliti, G Morone, and A Fusco; <italic>University Hospital
Policlinico Vittorio Emanuele, Catania</italic>: F Patti, C Cavallaro, A
Pappalardo, V Cascio, G Occhipinti, V Cimino, and F Zagari.</p><p>Other Centers and Investigators: <italic>AISM Liguria Region Rehabilitation
Service, Genoa</italic>: ML Lopes de Carvalho, M Giuntoli, R Motta, and
MA Battaglia; <italic>G d&#x02019;Annunzio University, Chieti-Pescara,
Chieti</italic>: A Lugaresi, E Pietrolongo, and M Onofrj; <italic>FARO
Charitable Foundation, Turin</italic>: S Veronese and C Cugno;
<italic>Niguarda Ca&#x02019; Granda Hospital, Milan</italic>: R Causarano and D
Da Col; <italic>Antea Charitable Association, Rome</italic>: G Casale and MC
Stefanelli; <italic>Foundation IRCCS Istituto Nazionale per la Cura dei
Tumori, Milan</italic>: C Borreani and E Bianchi.</p></sec></app></app-group><ref-list><title>References</title><ref id="bibr1-1352458517704078"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lublin</surname><given-names>FD</given-names></name><name><surname>Reingold</surname><given-names>SC.</given-names></name></person-group>
<article-title>Defining the clinical course of multiple sclerosis: Results of an
international survey</article-title>. <source>Neurology</source>
<year>1996</year>; <volume>46</volume>:
<fpage>907</fpage>&#x02013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">8780061</pub-id></mixed-citation></ref><ref id="bibr2-1352458517704078"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scalfari</surname><given-names>A</given-names></name><name><surname>Cutter</surname><given-names>G</given-names></name><name><surname>Goodin</surname><given-names>DS</given-names></name><etal>et al</etal></person-group>
<article-title>Mortality in patients with multiple
sclerosis</article-title>. <source>Neurology</source>
<year>2013</year>; <volume>81</volume>:
<fpage>184</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">23836941</pub-id></mixed-citation></ref><ref id="bibr3-1352458517704078"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fox</surname><given-names>RJ</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Setting a research agenda for progressive
multiple sclerosis: The International Collaborative on Progressive
MS</article-title>. <source>Mult Scler</source>
<year>2012</year>; <volume>18</volume>:
<fpage>1534</fpage>&#x02013;<lpage>1540</lpage>.<pub-id pub-id-type="pmid">22917690</pub-id></mixed-citation></ref><ref id="bibr4-1352458517704078"><label>4</label><mixed-citation publication-type="book">
<collab>NICE</collab>. <source>Multiple sclerosis in adults: Management
(CG186)</source>. <publisher-loc>London</publisher-loc>:
<publisher-name>NICE</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="bibr5-1352458517704078"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edmonds</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care for people severely affected by
multiple sclerosis: Evaluation of a novel palliative care
service</article-title>. <source>Mult Scler</source>
<year>2010</year>; <volume>16</volume>:
<fpage>627</fpage>&#x02013;<lpage>636</lpage>.<pub-id pub-id-type="pmid">20305044</pub-id></mixed-citation></ref><ref id="bibr6-1352458517704078"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Golla</surname><given-names>H</given-names></name><name><surname>Galushko</surname><given-names>M</given-names></name><name><surname>Pfaff</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Multiple sclerosis and palliative
care&#x02014;Perceptions of severely affected multiple sclerosis patients and their
health professionals: A qualitative study</article-title>. <source>BMC
Palliat Care</source>
<year>2014</year>; <volume>13</volume>: <fpage>11</fpage>.<pub-id pub-id-type="pmid">24641905</pub-id></mixed-citation></ref><ref id="bibr7-1352458517704078"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turner-Stokes</surname><given-names>L</given-names></name><name><surname>Sykes</surname><given-names>N</given-names></name><name><surname>Silber</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>From diagnosis to death: Exploring the interface
between neurology, rehabilitation and palliative care in managing people
with long-term neurological conditions</article-title>. <source>Clin
Med</source>
<year>2007</year>; <volume>7</volume>:
<fpage>129</fpage>&#x02013;<lpage>136</lpage>.</mixed-citation></ref><ref id="bibr8-1352458517704078"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Provinciali</surname><given-names>L</given-names></name><name><surname>Carlini</surname><given-names>G</given-names></name><name><surname>Tarquini</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Need for palliative care for neurological
diseases</article-title>. <source>Neurol Sci</source>
<year>2016</year>; <volume>37</volume>:
<fpage>1581</fpage>&#x02013;<lpage>1587</lpage>.<pub-id pub-id-type="pmid">27299428</pub-id></mixed-citation></ref><ref id="bibr9-1352458517704078"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliver</surname><given-names>DJ</given-names></name><name><surname>Borasio</surname><given-names>GD</given-names></name><name><surname>Caraceni</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>A consensus review on the development of
palliative care for patients with chronic and progressive neurological
disease</article-title>. <source>Eur J Neurol</source>
<year>2016</year>;
<volume>23</volume>:<fpage>30</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">26423203</pub-id></mixed-citation></ref><ref id="bibr10-1352458517704078"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veronese</surname><given-names>S</given-names></name><name><surname>Gallo</surname><given-names>G</given-names></name><name><surname>Valle</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Specialist palliative care improves the quality
of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised
controlled study</article-title>. <source>BMJ Support Palliat Care</source>.
Epub ahead of print <day>16</day>
<month>7</month>
<year>2015</year> DOI: <pub-id pub-id-type="doi">10.1136/bmjspcare-2014-000788.</pub-id></mixed-citation></ref><ref id="bibr11-1352458517704078"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Craig</surname><given-names>P</given-names></name><name><surname>Dieppe</surname><given-names>P</given-names></name><name><surname>Macintyre</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Medical research council guidance: Developing
and evaluating complex interventions: The new medical research council
guidance</article-title>. <source>BMJ</source>
<year>2008</year>; <volume>337</volume>: <fpage>a1655</fpage>.<pub-id pub-id-type="pmid">18824488</pub-id></mixed-citation></ref><ref id="bibr12-1352458517704078"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Grasso</surname><given-names>MG</given-names></name><etal>et al</etal></person-group>; <article-title>PeNSAMI Project. Home-based palliative approach
for people with severe multiple sclerosis and their carers: Study protocol
for a randomized controlled trial</article-title>. <source>Trials</source>
<year>2015</year>; <volume>16</volume>: <fpage>184</fpage> (Erratum in:
<italic>Trials</italic>
<year>2016</year>; <volume>17</volume>: <fpage>89</fpage>;
<italic>Trials</italic>
<year>2017</year>; <volume>18</volume>: <fpage>35</fpage>).<pub-id pub-id-type="pmid">25899519</pub-id></mixed-citation></ref><ref id="bibr13-1352458517704078"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polman</surname><given-names>CH</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name><name><surname>Banwell</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Diagnostic criteria for multiple sclerosis: 2010
revisions to the McDonald criteria</article-title>. <source>Ann
Neurol</source>
<year>2011</year>; <volume>69</volume>:
<fpage>292</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">21387374</pub-id></mixed-citation></ref><ref id="bibr14-1352458517704078"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>JF.</given-names></name></person-group>
<article-title>Rating neurologic impairment in multiple sclerosis: An expanded
disability status scale (EDSS)</article-title>. <source>Neurology</source>
<year>1983</year>; <volume>33</volume>:
<fpage>1444</fpage>&#x02013;<lpage>1452</lpage>.<pub-id pub-id-type="pmid">6685237</pub-id></mixed-citation></ref><ref id="bibr15-1352458517704078"><label>15</label><mixed-citation publication-type="web">
<collab>Prognostic Indicator Guidance (PIG).</collab>
<ext-link ext-link-type="uri" xlink:href="http://www.goldstandardsframework.org.uk/cd-content/uploads/files/General%20Files/Prognostic%20Indicator%20Guidance%20October%202011.pdf">http://www.goldstandardsframework.org.uk/cd-content/uploads/files/General%20Files/Prognostic%20Indicator%20Guidance%20October%202011.pdf</ext-link>
(<comment>accessed 15 January 2017</comment>).</mixed-citation></ref><ref id="bibr16-1352458517704078"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borreani</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>E</given-names></name><name><surname>Pietrolongo</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Unmet needs of people with severe multiple
sclerosis and their carers: Qualitative findings for a home-based
intervention</article-title>. <source>PLoS ONE</source>
<year>2014</year>; <volume>9</volume>: <fpage>e109679</fpage>.<pub-id pub-id-type="pmid">25286321</pub-id></mixed-citation></ref><ref id="bibr17-1352458517704078"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sep&#x000fa;lveda</surname><given-names>C</given-names></name><name><surname>Marlin</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Palliative care: The World Health Organization&#x02019;s
global perspective</article-title>. <source>J Pain Symptom Manage</source>
<year>2002</year>; <volume>24</volume>:
<fpage>91</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">12231124</pub-id></mixed-citation></ref><ref id="bibr18-1352458517704078"><label>18</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>O&#x02019;Boyle</surname><given-names>CA</given-names></name><name><surname>McGee</surname><given-names>HM</given-names></name><name><surname>Hickey</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<source>The Schedule for the Evaluation of Individual Quality
of Life (SEIQoL). Administration manual</source>.
<publisher-loc>Dublin</publisher-loc>: <publisher-name>Royal College of
Surgeons in Ireland</publisher-name>, <year>1993</year>.</mixed-citation></ref><ref id="bibr19-1352458517704078"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higginson</surname><given-names>IJ</given-names></name><name><surname>Donaldson</surname><given-names>N.</given-names></name></person-group>
<article-title>Relationship between three palliative care outcome
scales</article-title>. <source>Health Qual Life Outcomes</source>
<year>2004</year>; <volume>2</volume>: <fpage>68</fpage>.<pub-id pub-id-type="pmid">15566627</pub-id></mixed-citation></ref><ref id="bibr20-1352458517704078"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sleeman</surname><given-names>KE</given-names></name><name><surname>Higginson</surname><given-names>IJ.</given-names></name></person-group>
<article-title>A psychometric validation of two brief measures to assess
palliative need in patients severely affected by multiple
sclerosis</article-title>. <source>J Pain Symptom Manage</source>
<year>2013</year>; <volume>46</volume>:
<fpage>406</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">23195389</pub-id></mixed-citation></ref><ref id="bibr21-1352458517704078"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Coons</surname><given-names>SJ</given-names></name><name><surname>Ergo</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Valuation of EuroQOL (EQ-5D) health states in an
adult US sample</article-title>. <source>Pharmacoeconomics</source>
<year>1998</year>; <volume>13</volume>:
<fpage>421</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">10178666</pub-id></mixed-citation></ref><ref id="bibr22-1352458517704078"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP.</given-names></name></person-group>
<article-title>The hospital anxiety and depression scale</article-title>.
<source>Acta Psychiatr Scand</source>
<year>1983</year>; <volume>67</volume>:
<fpage>361</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation></ref><ref id="bibr23-1352458517704078"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keith</surname><given-names>RA</given-names></name><name><surname>Granger</surname><given-names>CV</given-names></name><name><surname>Hamilton</surname><given-names>BB</given-names></name><etal>et al</etal></person-group>
<article-title>The functional independence measure: A new tool
for rehabilitation</article-title>. <source>Adv Clin Rehabil</source>
<year>1987</year>; <volume>1</volume>:
<fpage>6</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">3503663</pub-id></mixed-citation></ref><ref id="bibr24-1352458517704078"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponzio</surname><given-names>M</given-names></name><name><surname>Gerzeli</surname><given-names>S</given-names></name><name><surname>Brichetto</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Economic impact of multiple sclerosis in Italy:
Focus on rehabilitation costs</article-title>. <source>Neurol Sci</source>
<year>2015</year>; <volume>36</volume>:
<fpage>227</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">25109816</pub-id></mixed-citation></ref><ref id="bibr25-1352458517704078"><label>25</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<source>SF-36 health survey manual and interpretation
guide</source>. <publisher-loc>Boston, MA</publisher-loc>:
<publisher-name>The Health Institute</publisher-name>,
<year>1993</year>.</mixed-citation></ref><ref id="bibr26-1352458517704078"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#x000e9;rbert</surname><given-names>R</given-names></name><name><surname>Bravo</surname><given-names>G</given-names></name><name><surname>Pr&#x000e9;ville</surname><given-names>M.</given-names></name></person-group>
<article-title>Reliability, validity, and reference values of the Zarit Burden
Interview for assessing informal caregivers of community-dwelling older
persons with dementia</article-title>. <source>Can J Aging</source>
<year>2000</year>; <volume>19</volume>:
<fpage>494</fpage>&#x02013;<lpage>507</lpage>.</mixed-citation></ref><ref id="bibr27-1352458517704078"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Cimino</surname><given-names>V</given-names></name><name><surname>Campanella</surname><given-names>A</given-names></name><etal>et al</etal></person-group>; <article-title>PeNSAMI Project. Low quality of life and
psychological wellbeing contrast with moderate perceived burden in carers of
people with severe multiple sclerosis</article-title>. <source>J Neurol
Sci</source>
<year>2016</year>; <volume>366</volume>:
<fpage>139</fpage>&#x02013;<lpage>145</lpage>.<pub-id pub-id-type="pmid">27288793</pub-id></mixed-citation></ref><ref id="bibr28-1352458517704078"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kavalieratos</surname><given-names>D</given-names></name><name><surname>Corbelli</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Association between palliative care and patient
and caregiver outcomes: A systematic review and
meta-analysis</article-title>. <source>JAMA</source>
<year>2016</year>; <volume>316</volume>:
<fpage>2104</fpage>&#x02013;<lpage>2114</lpage>.<pub-id pub-id-type="pmid">27893131</pub-id></mixed-citation></ref><ref id="bibr29-1352458517704078"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaertner</surname><given-names>J</given-names></name><name><surname>Siemens</surname><given-names>W</given-names></name><name><surname>Daveson</surname><given-names>BA</given-names></name><etal>et al</etal></person-group>
<article-title>Of apples and oranges: Lessons learned from the
preparation of research protocols for systematic reviews exploring the
effectiveness of specialist palliative care</article-title>. <source>BMC
Palliat Care</source>
<year>2016</year>; <volume>15</volume>: <fpage>43</fpage>.<pub-id pub-id-type="pmid">27091056</pub-id></mixed-citation></ref><ref id="bibr30-1352458517704078"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Methley</surname><given-names>AM</given-names></name><name><surname>Chew-Graham</surname><given-names>CA</given-names></name><name><surname>Cheraghi-Sohi</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>A qualitative study of patient and professional
perspectives of healthcare services for multiple sclerosis: Implications for
service development and policy</article-title>. <source>Health Soc Care
Community</source>. Epub ahead of print <day>11</day>
<month>7</month>
<year>2016</year> DOI: <pub-id pub-id-type="doi">10.1111/hsc.12369.</pub-id></mixed-citation></ref><ref id="bibr31-1352458517704078"><label>31</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Solari</surname><given-names>A.</given-names></name></person-group>
<article-title>Clinical trials to test rehabilitation</article-title>. In:
<person-group person-group-type="editor"><name><surname>Kesserling</surname><given-names>J</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group> (eds) <source>Multiple sclerosis: Recovery of function and
neurorehabilitation</source>. <publisher-loc>Cambridge</publisher-loc>:
<publisher-name>Cambridge University Press</publisher-name>,
<year>2010</year>,
pp.<fpage>157</fpage>&#x02013;<lpage>164</lpage>.</mixed-citation></ref><ref id="bibr32-1352458517704078"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hussain</surname><given-names>JA</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Langan</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Missing data in randomized controlled trials
testing palliative interventions pose a significant risk of bias and loss of
power: A systematic review and meta-analyses</article-title>. <source>J Clin
Epidemiol</source>
<year>2016</year>; <volume>74</volume>:
<fpage>57</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">26718729</pub-id></mixed-citation></ref><ref id="bibr33-1352458517704078"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giovannetti</surname><given-names>AM</given-names></name><name><surname>Pietrolongo</surname><given-names>E</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><etal>et al</etal></person-group>; <article-title>PeNSAMI Project. Individualized quality of life
of severely affected multiple sclerosis patients: Practicability and value
in comparison with standard inventories</article-title>. <source>Qual Life
Res</source>
<year>2016</year>; <volume>25</volume>:
<fpage>2755</fpage>&#x02013;<lpage>2763</lpage>.<pub-id pub-id-type="pmid">27125955</pub-id></mixed-citation></ref></ref-list></back></article>